Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/25 08:50
Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock?
Zacks · 06/17 14:43
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
GlobeNewswire · 06/15 13:00
Navidea Biopharma Reports Full Enrollment In Ongoing Phase 2b Trial OF Tc99m Tilmanocept In Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce
Benzinga · 06/15 12:19
Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series
GlobeNewswire · 06/09 12:30
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress
GlobeNewswire · 06/03 12:30
Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At The European League Against Rheumatism (EULAR) Congress
DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.